Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BASF Corporation is currently managing a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The prosecution profile shows 2 pending office actions, which represent the company's current active negotiations with the patent office. These actions are both located within 1 distinct art unit, suggesting that the technical subject matter of these applications is closely related and falls under the jurisdiction of a single specialized examination group. This concentration allows for a focused technical approach within that specific division.
The examination of these matters involves 2 distinct examiners, so each pending action is being reviewed by a different individual. KETCHAM, KAREN A is the busiest examiner for this portfolio and is currently handling 1 pending office action. While both actions are in the same art unit, the involvement of 2 different examiners means the company must address 2 separate sets of feedback. This structure requires managing the distinct perspectives of KETCHAM, KAREN A and the other assigned examiner to advance the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KETCHAM, KAREN A | 1 | 20.0% | +38.8% |
| JUSTICE, GINA CHIEUN YU | 1 | 55.6% | +8.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17416049 | NOVEL COSMETIC AND DERMATOLOGICAL USES OF AN EXTRACT OF CISTUS MONSPELIENSIS | JUSTICE, GINA CHIEUN YU | 28d |
| 18805874 | NEW COSMETIC USE OF POROUS SPHERES OF METAL OXIDE | KETCHAM, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18805874 | NEW COSMETIC USE OF POROUS SPHERES OF METAL OXIDE | KETCHAM, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18805874 | NEW COSMETIC USE OF POROUS SPHERES OF METAL OXIDE | KETCHAM, KAREN A | — | §103 | Non-Final OA | — | Pending | Aug 15, 2024 |
| 17416049 | NOVEL COSMETIC AND DERMATOLOGICAL USES OF AN EXTRACT OF CISTUS MONSPELIENSIS | JUSTICE, GINA CHIEUN YU | 1617 | §102§103§112 | Final Rejection | 28d | Pending | Mar 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial